Spectroscopic and electrochemical study for evaluating DNA interaction activity of 4‐(3‐halophenyl)‐6‐(pyridin‐2‐yl)pyrimidin‐2‐amine based piano stool Cp* Rh (III) and Ir (III) complexes

Vekariya, Pankajkumar A.; Karia, Parag S.; Bhatt, Bhupesh S.; Patel, Mohan N.

doi:10.1002/aoc.5152

Cited by 11 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential of transition metal complexes in medicine was recognized after the revolutionary discovery of cisplatin in cancer therapy [1], which stimulates the attention of bioinorganic researchers to synthesize metal-based compounds and their biological screening [2][3][4][5][6][7]. The mechanism of anticancer drugs includes programmed cell death or cell apoptosis by activation of intracellular death program, and accidental cell death due to trauma or nutrition deficiency which is called cell necrosis.…”

Section: Introductionmentioning

confidence: 99%

Mechanistic insight of cell anti-proliferative activity of fluoroquinolone drug-based Cu(II) complexes

et al. 2021

Self Cite

View full text Add to dashboard Cite

Pefloxacin-based mixed ligand Cu(II) complexes with substituted isatin of type [Cu(Isatin)(Pefloxacin)Cl] were synthesized, and characterized by EPR, mass, FT-IR, electronic spectrometry, metal content, magnetic moment, and conductance measurement. The g factors g ∥ > g ⟂ > 2.0023 observed in EPR suggest a square-pyramidal environment of ligands around the copper metal. The compounds were screened for diverse biological activities. The compounds inhibit efficiently the cell proliferation of HCT 116 cancer cells. To take the insight of anticancer activity mechanism, we investigated compound-1 for further cellular assay-based biological activities like trypan blue assay, cell morphological alteration assay, colony formation assay, cell apoptosis, and cell necrosis assay. The compound-1 induced distinct morphological alteration in cells, inhibits cell viability, decreases % plating efficiency, and decreases the clonogenic ability of the HCT 116 cells. The cell death mechanism was confirmed by annexin V-FITC / PI assay and LDH release assay. The positive annexin V/PI stained cells in presence of compound-1 and the absence of a significant amount of lactate dehydrogenase suggest cell apoptosis mechanism for anticancer activity of compounds. We also screened compounds for in vitro antibacterial and cytotoxic activities.

show abstract

Section: Introductionmentioning

confidence: 99%

Mechanistic insight of cell anti-proliferative activity of fluoroquinolone drug-based Cu(II) complexes

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Synthesis and biological evaluations of mono‐ and bis‐ferrocene uracil derivatives

Djaković

Glavaš‐Obrovac

Lapić

et al. 2020

Applied Organom Chemis

View full text Add to dashboard Cite

Mono-(3a-3e and 4a-4e) and bis-ferrocene (5a-5e and 6a-6e) conjugated 5-substituted uracil derivatives that are bridged by 1,2,3-triazole linker were synthesized. The impact of ferrocene unit and spacer between ferrocene and triazole on radical scavenging potency was observed. Bis-ferrocenyl uracil derivatives exhibited better antiproliferative activities than their monoferrocenyl analogs. Bis-ferrocenyl methyl-(5b) and halogen-substituted (5e, 6c, and 6d) uracil derivatives showed pronounced and selective cytostatic activities on colon adenocarcinoma (CaCo-2) and Burkitt lymphoma (Raji) cells, with higher potency and selectivity than the reference drug 5-fluorouracil. Generation of reactive oxygen species (ROS) in CaCo-2 and Raji cells when treated with compounds 5b, 5e, and 6d was observed. Bisferrocenyl 5-chlorouracil 6c induced significant disruption in mitochondrial membrane potential that is accompanied by activation of apoptosis in CaCo-2, Raji, and acute lymphoblastic leukemia (CCRF-CEM) cells, while 6d caused mitochondrial dysfunction and apoptosis induction in CaCo-2 and Raji cells. Potent antiproliferative activity of 6c and 6d could be associated with mitochondrial membrane potential disruption accompanied by apoptosis induction. Our findings highlighted 6c and 6d with potent and selective antiproliferative activity on CaCo-2, Raji, and CCRF-CEM cells that may be associated with targeting cancer cell mitochondria, as a molecular target.

show abstract

Aminobenzimidazole‐based (η⁶‐p‐cymene)ruthenium (II) complexes as nascent anticancer chemotherapeutics: Synthesis, crystal structure, DFT studies, HSA interactions, molecular docking, and cytotoxicity

Khan

AlFawaz

Farshori

et al. 2022

Applied Organom Chemis

View full text Add to dashboard Cite

Two half‐sandwich organometallic ruthenium (II) complexes containing analogs of aminobenzimidazole of molecular formula [η6‐p‐cymene)Ru (LH)Cl2] 1 and [η6‐p‐cymene)Ru (LMe)Cl2] 2, where LH and LMe represent 2‐aminobenzimidazole and 2‐amino‐1‐methylbenzimidazole, respectively, have been synthesized and characterized by FT‐IR, NMR (1H, 13C), ESI‐MS, elemental analysis, and single X‐ray crystallography (for 1). Both complexes 1 and 2 were studied for human serum albumin (HSA) binding affinity using intrinsic, synchronous, three‐dimensional (3D) fluorescence, thermodynamics parameter, and Förster resonance energy transfer (FRET) analysis. The Stern–Volmer constant (KSV) values are of the order of ×105 M−1 and increases in KSV with temperature ascertained the static quenching. The molecular docking of both the complexes with HSA was carried out to ascertain the binding sites/pockets. Furthermore, compounds were evaluated for their cytotoxic potential against three human cancer cell lines, namely, HeLa, HepG2, MCF‐7, and non‐tumorigenic HEK293 cells. The IC50 value of 2 was found to <10 μM against Hela and HepG2 cancer cells and has better cytotoxic properties than cisplatin (a standard drug), yet showed minimal toxicity against HEK293 cells. These results suggest further investigation for the development of ruthenium complex 2 as potential anticancer therapeutics.

show abstract

Spectroscopic and electrochemical study for evaluating DNA interaction activity of 4‐(3‐halophenyl)‐6‐(pyridin‐2‐yl)pyrimidin‐2‐amine based piano stool Cp* Rh (III) and Ir (III) complexes

Cited by 11 publications

References 58 publications

Mechanistic insight of cell anti-proliferative activity of fluoroquinolone drug-based Cu(II) complexes

Mechanistic insight of cell anti-proliferative activity of fluoroquinolone drug-based Cu(II) complexes

Synthesis and biological evaluations of mono‐ and bis‐ferrocene uracil derivatives

Aminobenzimidazole‐based (η⁶‐p‐cymene)ruthenium (II) complexes as nascent anticancer chemotherapeutics: Synthesis, crystal structure, DFT studies, HSA interactions, molecular docking, and cytotoxicity

Contact Info

Product

Resources

About

Spectroscopic and electrochemical study for evaluating DNA interaction activity of 4‐(3‐halophenyl)‐6‐(pyridin‐2‐yl)pyrimidin‐2‐amine based piano stool Cp* Rh (III) and Ir (III) complexes

Cited by 11 publications

References 58 publications

Mechanistic insight of cell anti-proliferative activity of fluoroquinolone drug-based Cu(II) complexes

Mechanistic insight of cell anti-proliferative activity of fluoroquinolone drug-based Cu(II) complexes

Synthesis and biological evaluations of mono‐ and bis‐ferrocene uracil derivatives

Aminobenzimidazole‐based (η6‐p‐cymene)ruthenium (II) complexes as nascent anticancer chemotherapeutics: Synthesis, crystal structure, DFT studies, HSA interactions, molecular docking, and cytotoxicity

Contact Info

Product

Resources

About

Aminobenzimidazole‐based (η⁶‐p‐cymene)ruthenium (II) complexes as nascent anticancer chemotherapeutics: Synthesis, crystal structure, DFT studies, HSA interactions, molecular docking, and cytotoxicity